Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004541 | 0.80 | PTGS2 (0.39) | PTGS1PTGS2TDO2KMT2ANPC1 | |
| SCHEMBL11593511 | 0.78 | PTGS1 (0.51) | PTGS1PTGS2TDO2GAAMEN1 | |
| SCHEMBL2092874 | 0.77 | NR1H4 (0.42) | BRD4BRD2PTGS1PTGS2L3MBTL1 | |
| SCHEMBL16863686 | 0.75 | PTGS1 (0.42) | BRD4BRD2PTGS1PTGS2TDO2 | |
| SCHEMBL3645802 | 0.75 | S1PR1 (0.40) | BRD4BRD2PTGS1PTGS2TDO2 | |
| SCHEMBL1086652 | 0.73 | PTGS1 (0.47) | PTGS1PTGS2KMT2ANPC1RAB9A | |
| SCHEMBL1086256 | 0.73 | NPC1 (0.45) | PTGS1GAAL3MBTL1MEN1KMT2A | |
| SCHEMBL6452695 | 0.72 | ALDH1A1 (0.38) | BRD4BRD2PTGS1PTGS2L3MBTL1 | |
| SCHEMBL3150963 | 0.72 | MEN1 (0.38) | BRD4BRD2PTGS1PTGS2TDO2 | |
| SCHEMBL6452700 | 0.71 | NOTUM (0.43) | PTGS1PTGS2TDO2L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424926-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINS, THEIR PRODUCTION AND UTILISATION AS MEDICINE | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2019-01-09 | — | — | EP | claimed |
| US-10016420-B2 | Substituted pyridazines for the treatment of pain | INHIBITAXIN LIMITED (GB) | 2018-07-10 | — | — | US | claimed |
| EP-3243815-A1 | PYRIDAZINE DERIVATIVES USEFUL IN THERAPY | Inhibitaxin Limited (GB) | 2017-11-15 | — | — | EP | claimed |
| CN-105367508-B | A kind of preparation method of Parecoxib Sodium synthesis technique impurity | 蚌埠丰原医药科技发展有限公司 | 2017-09-29 | — | — | CN | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| US-20160287584-A1 | SUBSTITUTED PYRIDAZINES FOR THE TREATMENT OF PAIN | INHIBITAXIN LTD (GB) | 2016-10-06 | — | — | US | claimed |
| US-9359310-B2 | Methanethione compounds having antiviral activity | VIRONOVA INFLUENZA AB (SE) | 2016-06-07 | — | — | US | claimed |
| CN-105367508-A | Preparation method of parecoxib sodium synthesis technology impurities | BENGBU BBCA MEDICINE SCIENCE & DEV CO LTD | 2016-03-02 | — | — | CN | claimed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | claimed |
| US-8809010-B2 | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases | PROBIODRUG AG (DE) | 2014-08-19 | — | — | US | claimed |
| US-4166905-A | ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1979-09-04 | — | — | US | claimed |
| US-4163784-A | ACYLUREA DERIVATIVES | PFIZER INC. (US) | 1979-08-07 | — | — | US | claimed |
| EP-0000891-A1 | Synergistic combinations of penicillins and antibiotic agents containing them | BAYER AG (DE) | 1979-03-07 | — | — | EP | claimed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | claimed |
| US-4118566-A | Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-10-03 | — | — | US | claimed |
| US-4115385-A | PENICILLINS | PFIZER INC. (US) | 1978-09-19 | — | — | US | claimed |
| US-4113946-A | Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-09-12 | — | — | US | claimed |
| US-4112230-A | Δ2,3 -1,4 Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | claimed |
| US-4060687-A | Cephalosporins having a 3-α substituted alkyl grouping | MERCK & CO., INC. (US) | 1977-11-29 | — | — | US | claimed |
| US-3979508-A | PENICILLOYL-POLYLYSINE | KREMERS-URBAN COMPANY (US) | 1976-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016420-B2 | Substituted pyridazines for the treatment of pain | OPRM1, OPRL1, OPRK1 | BRD4 144/4885BRD2 1002/4885PTGS1 245/4885 |
| US-20160287584-A1 | SUBSTITUTED PYRIDAZINES FOR THE TREATMENT OF PAIN | OPRM1, OPRL1, OPRK1 | BRD4 144/4885BRD2 1002/4885PTGS1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.